33.44 - 34.57
31.40 - 61.90
7.61M / 5.95M (Avg.)
-152.73 | -0.22
Analyze analyst forecasts for the company and compare them with competitors.
919.36M
No peer data available for comparison.
-586.00M
No peer data available for comparison.
0.05
No peer data available for comparison.
31.13M
No peer data available for comparison.
-659.21M
No peer data available for comparison.
1.04B
No peer data available for comparison.
Analyze DCF forecasts for the company and compare them with competitors.
249.91M
Worse than PATH's revenue of 607.64M.
108.49%
Better than PATH's revenue growth rate of 80.76%.
-185.21M
Worse than PATH's ebitda of -90.72M.
-74.11%
Worse than PATH's ebitda margin of -14.93%.
-222.32M
Worse than PATH's ebit of -110.32M.
-88.96%
Worse than PATH's ebit margin of -18.16%.
37.11M
Worse than PATH's depreciation of 19.60M.
399.89M
Worse than PATH's total cash of 460.52M.
160.02%
Better than PATH's cash as percentage of revenue of 75.79%.
42.25M
Better than PATH's receivables of 217.69M.
16.91%
Better than PATH's receivables as percentage of revenue of 35.82%.
13.67M
Worse than PATH's inventories of 1.00.
5.47%
Worse than PATH's inventories as percentage of revenue of 0.00%.
19.40M
Worse than PATH's accounts payable of 6.68M.
7.76%
Worse than PATH's payables as percentage of revenue of 1.10%.
-32.10M
Better than PATH's capital expenditure of -3.19M.
-12.85%
Better than PATH's capex as percentage of revenue of -0.53%.
11.55%
Worse than PATH's weighted average cost of capital (wacc) of 8.47%.
11.58%
Worse than PATH's cost of equity of 8.51%.
4.40%
Equal to PATH's cost of debt of 4.40%.
1.52
Worse than PATH's beta of 0.87.
534.88M
Better than PATH's diluted shares outstanding of 563.86M.
99.49M
Worse than PATH's total debt of 67.07M.
23.34B
Better than PATH's total equity of 7.31B.
23.44B
Better than PATH's total capital of 7.38B.
0.42%
Better than PATH's debt weighting of 0.91%.
99.58%
Better than PATH's equity weighting of 99.09%.
-222.41M
Worse than PATH's ebiat of -107.68M.
-219.66M
Worse than PATH's unlevered free cash flow of -167.47M.
2.00%
Equal to PATH's long-term growth rate of 2.00%.
-99.35B
Worse than PATH's terminal value of -66.62B.
-71.64B
Worse than PATH's enterprise value of -53.14B.
-36.05M
Worse than PATH's net debt of -994.61M.
-71.60B
Worse than PATH's equity value of -52.15B.
-133.86
Worse than PATH's equity value per share of -92.48.
View analysts' price targets and recommendations, and compare them with competitors.
$49.00
Analysts expect the stock price to increase by 45.83%.
Buy
Positive consensus among analysts.
